Phoenix Bio

研究発表

研究発表

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

    Jain, R. Frederick, J. P. Huang, E. Y. Burke, K. E. Mauger, D. M. Andrianova, E. A. Farlow, S. J.Siddiqui, S. Pimentel, J. Cheung-Ong, K. McKinney, K. M. Kohrer, C. Moore, M. J. Chakraborty, T.

    Nucleic Acid Ther. 2018 Oct;28(5):285-296.

    Chimeric mice with human hepatocytes: A new system for genotoxicity studies

      C. Tateno, M. Fukumuro, S. Masumori, M. Kakuni, Y. Ishida, T. Shimada, M. Hayashi

      Mutat Res. 2019 Mar;839:9-12

      Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver

        Harimoto, N. Nakagawara, H. Shirabe, K. Yoshizumi, T. Itoh, S. Ikegami, T. Soejima, Y. Maehara, Y. Ishida, Y. Tateno, C. Tanaka, Y.

        Transplant Proc. 2018 Dec;50(10):3858-3862. doi: 10.1016/j.transproceed.2018.06.035.

        Lack of human relevance for procymidone’s developmental toxicity attributable to species difference in its kinetics and metabolism

          Tomigahara, Y. Tarui, H. Matsui, M. Kurosawa, M. Kawamura, S. Isobe, N.

          J Pestic Sci. 2018 May 20;43(2):114-123. doi: 10.1584/jpestics.D17-085.

          Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model

            Ye, X. Tateno, C. Thi, E. P. Kakuni, M. Snead, N. M. Ishida, Y. Barnard, T. R. Sofia, M. Shimada, T. Lee, A. C. H.

            ACS Infect Dis. 2018 Nov 8. doi: 10.1021/acsinfecdis.8b00192.

            ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection

              Thi, E. P. Dhillon, A. P. Ardzinski, A. Bidirici-Ertekin, L. Cobarrubias, K. D. Cuconati, A. Kondratowicz, A. S. Kwak, K. Li, A. H. L. Miller, A. Pasetka, C. Pei, L.Phelps, J. R. Snead, N. M. Wang, X. Ye, X. Sofia, M. J. Lee, A. C. H.

              ACS Infect Dis. 2018 Nov 19. doi: 10.1021/acsinfecdis.8b00191.

              Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes

                Tsuge, M. Hiraga, N. Zhang, Y. Yamashita, M.  Sato, O. Oka, N. Shiraishi, K. Izaki, Y. Makokha, G. N. Uchida, T. Kurihara, M. Nomura, M. Tsushima, K. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Fujita, T. Chayama, K.

                Virology. 2018 Sep 18;525:48-61. doi: 10.1016/j.virol.2018.08.020.

                CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients

                  Nomura, M. Tsuge, M. Uchida, T. Hiraga, N. Kurihara, M. Tsushima, K. Fujino, H. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Hiramatsu, A. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Zhang, Y. Makokha, G. N. Hayes, C. N. Tanaka, S. Chayama, K.

                  J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12970.

                  The metabolic fate of fenclozic acid in chimeric mice with a humanized liver

                    Ekdahl, A. Weidolf, L. Baginski, M. Morikawa, Y. Thompson, R. A. Wilson, I. D.

                    Arch Toxicol. 2018 Sep;92(9):2819-2828.

                    Contribution of chimeric mice with a humanized liver to the evaluation of pharmacology, toxicity, and pharmacokinetics in drug discovery and development

                      Sanoh, S. Ohta, S.

                      Nihon Yakurigaku Zasshi. 2018;151(5):213-220

                      Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

                        Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                        J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

                        Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

                          Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.

                          Oncotarget. 2018 May 18;9(38):25075-25088.

                          The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice

                            de la Rosa Rodriguez, M. A. Sugahara, G. Hooiveld, Gjej Ishida, Y. Tateno, C. Kersten, S.

                            BMC Genomics. 2018 Jun 7;19(1):443. doi: 10.1186/s12864-018-4834-3.

                            Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

                              Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                              Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

                              Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions

                                Takaoka, N. Sanoh, S. Okuda, K. Kotake, Y. Sugahara, G. Yanagi, A. Ishida, Y. Tateno, C. Tayama, Y. Sugihara, K. Kitamura, S. Kurosaki, M. Terao, M. Garattini, E. Ohta, S.

                                Biochem Pharmacol. 2018 Apr 17;154:28-38.

                                FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver

                                  Papazyan, R. Liu, X. Liu, J. Dong, B. Plummer, E. M. Lewis, R. D., 2nd Roth, J. D. Young, M. A.

                                  J Lipid Res. 2018 Mar 20. pii: jlr.M081935. doi: 10.1194/jlr.M081935.

                                  Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

                                    Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

                                    Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

                                    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

                                      Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

                                      J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

                                      A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

                                        Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

                                        Antiviral Res. 2017 Dec 7;150:47-59.

                                        Hepatitis C replication inhibitors that target the viral NS4B protein

                                          Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

                                          J Med Chem. 2014 Mar 13;57(5):2107-20